SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation
Your view on ICUCW
Overview
What the company does, where it operates, and who runs it.
About SeaStar Medical Holding Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Eric Schlorff
- Headquarters
- 3513 Brighton Boulevard, Denver, CO, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Eric Schlorff
- Headquarters
- 3513 Brighton Boulevard, Denver, CO, US
Based in Denver, Colorado, SeaStar Medical Holding Corporation operates as a medical device company. Its primary mission is to develop innovative therapies and services designed to combat hyperinflammation and cytokine storm, particularly in critically ill individuals.
The company specializes in advancing and bringing to market extracorporeal treatments.
These therapies are engineered to specifically target the immune "effector cells" that fuel widespread systemic inflammation, which is known to cause direct tissue damage and unleash a cascade of pro-inflammatory cytokines, leading to dysregulated immune responses. SeaStar Medical's product pipeline extends across diverse therapeutic domains.
These include both pediatric and adult acute kidney injury, particularly when patients are undergoing continuous renal replacement therapy (CRRT); cardiorenal syndrome observed in cases of congestive heart failure, whether or not an LVAD is present; myocardial stunning associated with end-stage renal disease; and hepatorenal syndrome.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for SeaStar Medical Holding Corporation from FRC's valuation model, read against the market price. ICUCW last traded at $0.0081; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SeaStar Medical Holding Corporation. Starting points for SeaStar Medical Holding Corporation: EPS -$3.34, beta -1.04 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SeaStar Medical Holding Corporation. SeaStar Medical Holding Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SeaStar Medical Holding Corporation. Trailing twelve-month EPS for SeaStar Medical Holding Corporation stands at -$3.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings Estimate
| EPS | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | -$0.89 | -$3.66 | -$2.09 |
| Low estimate | -$0.89 | -$3.73 | -$2.13 |
| High estimate | -$0.89 | -$3.59 | -$2.05 |
| No. of analysts | 1 | 1 | 1 |
| Year-ago EPS | -$0.80 | -$5.86 | — |
| Growth | -11.2% | +37.5% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | $500000.00 | $2.00M | $3.00M |
| Low estimate | $500000.00 | $1.97M | $2.93M |
| High estimate | $500000.00 | $2.03M | $3.07M |
| No. of analysts | 1 | 1 | 2 |
| Year-ago revenue | $420000.00 | $1.23M | — |
| Growth | +19.0% | +62.1% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 13, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SeaStar Medical Holding Corporation. SeaStar Medical Holding Corporation has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SeaStar Medical Holding Corporation valued side by side against its closest peers. SeaStar Medical Holding Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold SeaStar Medical Holding Corporation, and how their positions are changing. At a $291,982 market value, institutional positions materially move SeaStar Medical Holding Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by SeaStar Medical Holding Corporation executives and directors. Shares of SeaStar Medical Holding Corporation have traded between $0.02 and $0.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SeaStar Medical Holding Corporation. Coverage tracks SeaStar Medical Holding Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of SeaStar Medical Holding Corporation.